Who are saproterin dihydrochloride's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Kuvan®.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/saproterin-dihydrochloride.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

saproterin dihydrochloride — Competitive Intelligence Brief

saproterin dihydrochloride (saproterin dihydrochloride) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cofactor replacement therapy. Area: Metabolic/Genetic Disorder.

marketed Cofactor replacement therapy Phenylalanine ammonia-lyase (PAL) cofactor Metabolic/Genetic Disorder Small molecule Live · refreshed every 30 min

Target snapshot

saproterin dihydrochloride (saproterin dihydrochloride) — University Hospitals Cleveland Medical Center. Saproterin dihydrochloride is a synthetic form of tetrahydrofolate that acts as a cofactor to enhance phenylalanine ammonia-lyase (PAL) enzyme activity, reducing blood phenylalanine levels in phenylketonuria.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
saproterin dihydrochloride TARGET	saproterin dihydrochloride	University Hospitals Cleveland Medical Center	marketed	Cofactor replacement therapy	Phenylalanine ammonia-lyase (PAL) cofactor
Kuvan®	Kuvan®	Merck KGaA, Darmstadt, Germany	marketed	Cofactor replacement therapy	Phenylalanine ammonia-lyase (PAL) enzyme cofactor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cofactor replacement therapy class)

Merck KGaA, Darmstadt, Germany · 1 drug in this class
University Hospitals Cleveland Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). saproterin dihydrochloride — Competitive Intelligence Brief. https://druglandscape.com/ci/saproterin-dihydrochloride. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab